 May 10, 2006
| Topic: |
Who benefits from drug studies? Challenges in International Research |
| Presenter: |
Wendy Bracken, San Diego State University |
| Location: |
SDSU Foundation: Sky Park |
| Discussion: |
Members of the poorest communities often serve as research participants in international drug trials. However, once the study has come to a close, treatments and/or drugs developed from these studies may not be made available to the communities that need them the most. In these cases, neither the principle of beneficence, (i.e., the obligation to protect persons from harm by maximizing anticipated benefits and minimizing possible risks of harm), nor justice (i.e., fairness in the distribution of research benefits and burdens) appear to be adhered to. |
Discussion
Questions:
|
- Are research participants receiving the best standard of care?
- What guidelines should be implemented in order to ensure that treatments and/or drugs are provided to those who need them most?
- Who should ensure that these guidelines are adhered to?
- Do participants understand the limitations to the care they receive?
|
| Readings: |
- Lo, Bernard; Bayer, Ronald. Education and debate. Establishing ethical trials for treatment and prevention of AIDS in developing countries. BMJ. 2003 August 9; 327(7410): 337339.
- MacQueen, Kathleen M; Karim, Quarraisha Abdool; Sugarman, Jeremy. Education and debate. Ethics guidance for HIV prevention trials. BMJ. 2003 August 9; 327(7410): 340.
- Jansen, Lynn A. A Closer Look at the Bad Deal Trial. The Hastings Center Report, September-October, 2005; 35,5. For a PDF copy, please contact Wendy Bracken.
|
|
